D. E. Shaw & Co., Inc. Cel Sci Corp Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Cel Sci Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 188,545 shares of CVM stock, worth $205,514. This represents 0.0% of its overall portfolio holdings.
Number of Shares
188,545
Previous 105,574
78.59%
Holding current value
$205,514
Previous $287,000
25.44%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CVM
# of Institutions
83Shares Held
7.5MCall Options Held
61.8KPut Options Held
141K-
Vanguard Group Inc Valley Forge, PA2.19MShares$2.39 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE879KShares$957,85612.54% of portfolio
-
Black Rock Inc. New York, NY763KShares$832,1520.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA669KShares$729,1980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$506,2050.0% of portfolio
About CEL SCI CORP
- Ticker CVM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,367,500
- Market Cap $47.3M
- Description
- CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...